Use of ligustrazine nitrone derivatives in treatment and prevention of diabetic complication diseases
US12377095B2 · kind B2 · utility
Inventors
Key dates
| Filing date | Nov 3, 2021 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Apr 18, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of ligustrazine nitrone derivatives and pharmaceutical composition thereof for the treatment and prevention of diseases of diabetic complications, which include renal anemia. The ligustrazine nitrone derivatives have the structure of the general formula (I). Experimental results indicated that the ligustrazine nitrone derivatives can significantly increase the levels of serum iron and erythropoietin in STZ induced SD rats and spontaneously hypertensive rats, and can be used for treating and preventing renal anemia caused by decrease in renal EPO production and/or concomitant iron deficiency. Therefore, the ligustrazine nitrone derivatives can be made into various dosage forms with a drug carrier. The derivatives can be prepared into various dose forms together with drug carriers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.